SCHEMBL4089879

SCHEMBL4089879

CC(C)(C)c1ccc(-c2nc(N3CCOCC3)c3ccccc3n2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.74
RAB9A P51151 1/20 0.74
KMT2A Q03164 1/20 0.74
TP53 P04637 3/20 0.73
HTT P42858 2/20 0.70
LMNA P02545 1/20 0.70
CYP1A2 P05177 6/20 0.65
ALDH1A1 P00352 5/20 0.65
ALOX15 P16050 4/20 0.65
CYP2C19 P33261 3/20 0.65
HSD17B10 Q99714 2/20 0.65
CYP3A4 P08684 5/20 0.63
USP2 O75604 4/20 0.63
CLK4 Q9HAZ1 4/20 0.63
TSHR P16473 3/20 0.63
GBA1 P04062 2/20 0.63
SMN1; SMN2 Q16637 1/20 0.62
MAPK1 P28482 3/20 0.61
CYP2C9 P11712 1/20 0.61
CASP7 P55210 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4096150 0.89 MEN1 (0.80) MEN1RAB9AKMT2ATP53LMNA
SCHEMBL4091461 0.88 HTT (0.73) MEN1RAB9AKMT2ATP53HTT
SCHEMBL4092367 0.88 KMT2A (0.78) MEN1RAB9AKMT2ATP53LMNA
SCHEMBL3748887 0.87 HTT (0.84) MEN1KMT2ATP53HTTLMNA
SCHEMBL4089287 0.86 RAB9A (0.98) MEN1RAB9AKMT2ATP53LMNA
SCHEMBL4088943 0.85 MEN1 (0.74) MEN1RAB9AKMT2ATP53HTT
SCHEMBL1083793 0.84 HTT (0.74) MEN1KMT2ATP53HTTLMNA
SCHEMBL13342122 0.84 HTT (0.74) TP53HTTLMNACYP1A2ALDH1A1
SCHEMBL1083989 0.84 HTT (0.74) MEN1KMT2ATP53HTTLMNA
SCHEMBL8619809 0.83 CYP3A4 (0.76) MEN1KMT2ATP53HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MEN1 718/4885RAB9A 640/4885KMT2A 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.